Glioma is the most common central nervous system tumor and associated with poor prognosis. Identifying effective diagnostic biomarkers for glioma is particularly important in order to guide optimizing treatment. MicroRNAs (miRNAs) have drawn much attention because of their diagnostic value in diverse cancers, including glioma. We summarized studies to identify the potential diagnostic values of miRNAs in glioma patients. We included articles reporting miRNAs for differentiation of glioma patients from controls. We calculated sensitivities, specificities, and area under the curves (AUC) of individual miRNA and miRNA panels. We found that overall sensitivity, specificity, and AUC of miRNAs in diagnosis of glioma were 85% 
diagnostic markers and new therapies for glioma are urgently needed.
Molecular profiling of cancer has attracted a large amount of attention because of its clinical value in diagnosis, prognosis, and treatment of patients. 4 Thus, finding useful molecular markers to guide clinicians in optimizing treatment of glioma patients is important. miRNAs are a class of small non-coding RNA with [19] [20] [21] [22] nucleotides. miRNAs have been found to be closely related to cancers because of the alterations in target binding sites of miRNAs and the miRNA processing machinery in tumor cells. 5 Recently, expression of miRNA in glioma has been extensively examined.
Many studies have shown that some miRNAs are correlated with the diagnosis and prognosis of gliomas. For example, miR-301a is highly expressed in glioma serum exosomes and can be a diagnostic and prognostic indicator for glioma. 6 However, only two meta-analyses have studied the accuracy of diverse miRNAs for the diagnosis of glioma. 7 Ma et al 8 analyzed only the expression of miRNAs in blood samples. However, Akers et al 9 reported that miRNAs in CSF could serve as biomarkers for glioma. Moreover, new studies of miRNAs have been done since the publication of the meta-analyses of Qu et al 7 4 years ago. Therefore, we carried out a meta-analysis to identify the potential diagnostic values of miRNAs in glioma patients.
| MATERIALS AND METHODS

| Search strategy
We carefully searched literature databases (PubMed, EMBASE, Cochrane Library, and Web of Science) to identify relevant studies published through June 13, 2018 . The searches typically included 3 key terms "glioma," "miRNA," and "diagnosis." We searched PubMed using the following strategy: ((((( "MicroRNAs"[Mesh] )
OR (((((((((((((((((MicroRNA[Title/Abstract] ((((((((((((((((((Gliomas[Title/Abstract] ((((((((((Diagnoses[Title/Abstract] (ii) not conducted on humans; (iii) reviews, letters, and meeting records; (iv) glioma and miRNAs were not studied; (v) studies focusing on gene polymorphisms; (vi) sample cases were from a database;
and (vii) studies with insufficient data.
We assessed the quality of diagnostic studies based on the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria. 10 It consists of 4 key domains: patient selection, index test, reference standard, flow and timing and judge bias and applicability.
Each is assessed in terms of risk of bias, and the first 3 domains
were assessed with respect to applicability. Each item is answered with "yes," "no," or "unclear." The answer of "yes" means low risk of bias, whereas "no" or "unclear" means the opposite.
| Data extraction
Two reviewers (Zhou and Liu) independently extracted the data from the included studies using a standardized form. Data extraction included the following items: last name of the first author, publication year; study population and regions; false and true positives and negatives, and sample numbers.
| Statistical analysis
We extracted the number of TP, FP, FN, and TN of each study to calculate the pooled sensitivity, specificity, PLR, NLR, DOR, and corresponding 95% CI. We also tested the pooled diagnostic value of miRNAs through the SROC curve and the area under the SROC curve (AUC). In the present study, Deeks' funnel plot was also conducted to test publication bias. We assessed heterogeneity among the studies using the chi-squared and I 2 tests. If P <.1 or I 2 >50%, heterogeneity was defined as significant. We also conducted metaregression, subgroup and sensitivity analyses to identify potential sources of heterogeneity. We carried out all analyses using Review 6, 9, A flowchart of the selection process for this study is presented in Figure 1 .
In total, 28 articles (ranging from years 2009 to 2018) reported 51 studies, including 2528 glioma patients and 2563 controls comprising healthy controls and patients with other diseases (Table 1) . Among the 51 studies, 34 studies reported a single miRNA, whereas 17 studies discussed panel of miRNAs (Table S1 ).
The diagnostic values of single miRNA (miR-128, miR-125b, and miR-221) were conducted in 2 studies, whereas single miRNA (miR-222) and a panel of miRNAs (miR-15b and miR-21) were reported in 3 studies. As single miRNA (miR-21) was reported by 4 studies, we conducted a meta-analysis of miR-21. Among the 51 studies analyzed, 39 studies detected miRNA in blood, 6 studies detected miRNA in CSF and 6 studies researched brain tissue.
Of the 51 studies, 22 studies were conducted in Caucasian populations, and the remaining 29 studies focused on Asian populations.
| Quality assessment
Quality assessment results of all studies included in this meta-analysis are shown in Figure S1A ,B.
Articles retrieved from PubMed (454), EMBASE (596), Cochrane library (6), web of science (536) Articles after duplicates removed (1323) Articles after manual screened (754 
| Diagnosis
Sensitivity and specificity of miRNAs in diagnosing glioma are shown in Figure 2A ,B. From forest plots of pooled data (51 studies from 28 articles), we found significant heterogeneity and used a mixedeffects model in the present meta-analysis. Diagnostic accuracy, sensitivity, and specificity of all miRNAs are summarized in Table S2 . 5.4, 0.20, 27, 0.90; 0.90, 0.95, 19.8, 0.11, 185, 0.97 
| Sensitivity analysis, meta-regression analysis, and publication bias
For sensitivity analysis, goodness of fit and bivariate normality showed that random effects bivariate model is suitable (Figure S3A Figure S3D ).
After excluding 5 outlier studies, the I 2 value for heterogeneity decreased 7.8% for sensitivity and 5.46% for specificity ( Figure S4 ).
We read those studies again and conducted meta-regression analysis on the bias of ethnicity, miRNAs, and detected sample. We found that sensitivity was influenced by ethnicity, miRNAs and detected sample, whereas specificity was affected only by detected sample. The miRNA detected in CSF or tissue shows a higher sensitivity and specificity in the diagnosis of glioma. Moreover, funnel F I G U R E 2 Forest plots for studies on overall microRNAs (miRNAs) used in the diagnosis of glioma among 51 studies included in the present meta-analysis A, Sensitivity; B, Specificity plot showed no significant publication bias in the present metaanalysis ( Figure S5 ).
| DISCUSSION
This meta-analysis of 28 articles including 2528 glioma patients and 2563 controls showed that miRNAs maintained high sensitivity (0.85) and specificity (0.90) in glioma diagnosis. Pooled PLR was 8.2, indicating that the probability of glioma increased by 8.2-fold with positive miRNAs testing. Moreover, NLR was 0.16, implying that the probability of glioma increased by 84% when the studied miRNAs were negative. Although a DOR of 1 suggests miRNAs failed to differentiate glioma and control, the DOR of 50 in our study showed that miRNAs are outstanding biomarkers in glioma diagnosis.
There were only 2 meta-analyses investigating the diagnostic accuracy of diverse miRNAs in glioma patients. In a meta-analysis which were similar to our results. However, the investigators carried out only subgroup analyses of miRNA profiling to explore the sources of heterogeneity. According to our meta-regression analysis, miRNA profiling would influence sensitivity rather than specificity. | 2657 could only partly explain the source of heterogeneity. Several different cut-off values were used in the included studies, which may have contributed to the heterogeneity. Second, after using the Quality Assessment of Diagnostic Accuracy Studies, we found that all studies enrolled in this meta-analysis were retrospective casecontrol studies. Moreover, all of the index test results were interpreted with knowledge of the results of the reference standard and used thresholds were not pre-specified ( Figure S1 ). Third, studies with positive results are more likely to be published, which can amplify the overall diagnostic accuracy. Finally, we only included studies written in English, which may have affected our findings.
Helping clinical decision-making is the most important value of biomarkers. Likelihood ratios and post-test probabilities are helpful for clinicians because they supply information about the likelihood that a patient with a positive or negative test actually has glioma or not. We also summarized positive likelihood ratios and negative likelihood ratios to judge the clinical applicability of miRNAs for diagnosis ( Figure 5A ). PLR >10 and NLR <0.1 represent a high diagnostic accuracy. 37 We found that the miRNAs of the articles of , miRNA-106a-5p, miRNA-130a-3p, miRNA-181b-5p, miRNA-208a-3p) may be promising miRNAs and deserve future research. When the pretest probability was set at 20%, the post-test probability for a positive test result was 67%. When the negative likelihood ratio was set at 0.16, the post-test probability reduced to 4% for a negative test result ( Figure 5B ).
Our study indicated that miRNAs could be potential diagnostic biomarkers for glioma. Additionally, subgroup analysis indicated that miRNAs in CSF and tissues may improve the diagnostic accuracy. Also, panels of multiple miRNAs could discriminate patients with glioma more accurately than a single miRNA. However, largesized and good-quality studies should be conducted to verify our results and confirm the clinical value of miRNAs in glioma patients. 
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